Lifastuzumab vedotin

N/A

Report date: 2024/02/05 13:55:37

Base Information

Drug NameLifastuzumab vedotin
Drug Alias Name维汀-利法妥珠单抗lifastuzumab vedotina维利法妥组单抗lifastuzumabum vedotinumNaPi2b-ADC +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsSodium-dependent phosphate transport protein 2B inhibitors
TargetsSodium-dependent phosphate transport protein 2BTubulin
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia